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Abstract 
Toll-like receptors (TLRs) mediate interactions between environmental stimuli and innate 
immunity. TLRs play a major role in the development of numerous pancreatic diseases, making 
these molecules attractive as potential therapeutic targets. TLR2, TLR7 and TLR9 are involved in 
the initiation of type 1 diabetes mellitus (T1DM), whereas TLR2 and TLR4 play a major role in 
the onset of type 2 diabetes mellitus (T2DM). Furthermore, TLRs cause derangements in several 
tumour suppressor proteins (such as p16, p21, p27, p53 and pRb), induce STAT3 activation and 
promote epithelial–mesenchymal transition as well as oncogene-induced senescence. In this 
review we will focus on the contribution of TLRs in pancreatic disease including cancer and we 
describe recent progress in TLR-modulation for the treatment of these patients. 
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Introduction 
Activation of innate immunity is achieved through the stimulation of pattern recognition receptors 
(PRRs). Among them, Toll-like receptors (TLRs) were the first group to be identified. They can 
be activated by a panel of pathogen-associated molecular patterns (PAMPs) [1,2] and alarmins [3] 
endogenous molecules released by activated or necrotic cells in response to stress or tissue 
damage into the extracellular compartment [4]. 
Another feature of PPRs is their capability to recognize self-molecular patterns originated from 
damaged cells, named Damage Associated Molecular Patterns (DAMPs). 
TLRs are single-pass transmembrane proteins with an intracellular C-terminal tail known as the 
Toll/IL-1 receptor (TIR) and an extracellular N-terminal that contains leucine-rich repeats (LRRs). 
TLR ligation leads to activation of two major intracellular signalling pathways. All TLRs, except 
TLR3, can activate a Myeloid differentiation primary response protein 88 (MyD88)-dependent 
pathway (Figure 1). This pathway involves IL-1R-associated kinases (IRAK), Tumor Necrosis 
Factor (TNF) receptor-associated factor 6 (TRAF-6) and mitogen-activated kinases and leads to 
the transcription of pro-inflammatory genes through the activation of nuclear factor κβ (NFκB) 
and/or the activation of activating protein 1 [5,6]. Furthermore, TLR3 and TLR4 can activate the 
TIRAP inducing interferon β (TRIF) pathway, leading to the synthesis of interferon-α/β (IFN-α/β) 
[5]. 
At present, twelve TLRs have been identified in mice (TLR1 to TLR9 and TLR11 to TLR13) and 
ten in human (TLR1 to TLR10) [3]. Most TLRs are on the cell surface, except for TLR3, -7, -8, 
and -9, mainly present in the endosomes [2]. A further classification divides TLRs based on the 
type of recognized PAMPs: TLR1, TLR2, TLR4 and TLR6 detect lipids, whereas TLR5 and TLR 
10 recognize proteins and TLR3, TLR7, TLR8 and TLR9 detect nucleic acids [5]. The list of 
PAMPs and alarmins recognized by human TLRs is shown in Table 1. 
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The involvement of TLRs in the pathophysiology of several diseases has become a major research 
field [6,7]. This review summarizes the role of TLRs in the pathogenesis of inflammatory related 
pancreatic disease as well of pancreatic cancer, highlighting their potential use as future 
therapeutic targets.  
 
Methods 
Data for this Review were identified from the Pubmed database, using the subsequent MeSH 
(Medical Subject Heading) terms: "Inflammation", "Immune Response" "TLR”, “Toll-like 
receptor”, each combined with “Cancer”, “Diabetes”, “Pancreatitis”, “Pancreatic cancer”, 
“Pancreatic Ductal Adenocarcinoma”, “Sterile Inflammation”, and “Systemic Inflammatory 
Response Syndrome (SIRS)”. A further search was done of related articles and references from 
relevant papers. The ongoing trials were searched out on the official website 
www.clincaltrials.gov, with the last search on April 2014. No language was restricted. The final 
reference list was generated on the basis of originality and relevance to the broad scope of this 
Review. 
 
Role of TLRs in acute pancreatitis 
Acute pancreatitis (AP) is characterized by early activation of intracellular proteases followed by 
acinar cell death and inflammation. Mild acute pancreatitis (MAP), also known as edematous 
acute pancreatitis represents 80% of AP. While patients with MAP commonly recover without 
complication since MAP is a self-limited disease, in severe acute pancreatitis (SAP) (20%) there 
are frequent local and extrapancreatic complications inducing systemic inflammatory response 
syndrome (SIRS) and sequential multiple organ disfunction syndrome (MODS) [8]. 
Acinar and fat cells are the early cells damaged in AP, causing disregulation in basolateral 
secretion and enhanced ductal permeability. This event leads to early plasmatic increase of clinical 
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markers of pancreatic injury, such as lipase and amylase [9]. The intracellular protective 
mechanisms that prevent enzymes activation include synthesis of trypsin as inactive enzyme 
trypsinogen, autolysis of activated trypsin, enzyme compartmentalization, synthesis of specific 
trypsin inhibitors such as serine protease inhibitor Kazal type 1 (SPINK1), and lowering of 
intracellular ionized Ca2+ concentrations. 
A wider enzymatic activation, involving elastase phospholipase A2, complement and kinin 
pathways, occurs after tripsinogen activation into trypsin in acinar cells. These events cause gland 
autodigestion, local inflammation and lastly the release of intracellular contents from necrotic 
cells. The transendothelial migration of leucocytes amplifies the tissue damage, due to the release 
of leucocyte harmful enzymes, the generation of oxygen-derived free radicals and the increase of 
pancreas hypoxia caused by vessel damages, amplifying the pro-inflammatory condition [8].  
In health conditions, DAMPs are sequestered inside the cell, but after tissues injury, they are 
released in the extracellular space becoming available to cell surface PRRs. Since DAMPs engage 
the same PRRs as microbial agents, their inflammatory state has been indicated as “sterile 
inflammation” (Figure 2) [9]. This status involves TLRs (TLR4 or TLR9) and the signaling 
launched by the membrane purigenic receptor P2X and intracellular NOD-like receptors (NLR), 
which leads to the activation of Caspase 1, a cytosolic cystein protease that regulates the 
conversion of pro-cytokines into mature forms [9]. A number of DAMPS (such as high-mobility 
group box protein 1 (HMGB1), adenosine triphosphate and heat shock protein 70) have been 
shown to play a role in experimental pancreatitis. HMGB1 is released by injured acinar cells and 
acts as a proinflammatory cytokine with neoangiogenetic and chemotactic activity. It affects cell 
proliferation and regeneration of damaged tissues stimulating autophagy [10]. Furthermore, 
HMGB1 activates sterile inflammation through TLR, especially TLR4. TLR4 is expressed not 
only on immune system cells, but also in pancreatic ductal and endothelial cells or in tissue 
macrophages (thus called DAMP-sensing cells). Notably, TLR4 is not expressed in acinar cells 
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[9]. In mice with caerulein-induced pancreatitis (CIP), TLR4 deficiency is associated with a 
delayed development of pancreatitis [11]. Similarly, other reports show that acinar cell necrosis, 
edema and hemorrhage induced by taurocholate are significantly decreased in TLR4-deficient 
mice [12]. 
TLR9 is expressed in immune cells, pancreatic ductal and endothelial cells, but not in acinar cells. 
TLR9 recognizes microbial nucleic acid, specifically CpG motifs (unmethylated cytosine-
phosphate-guanine (CpG) dinucleotides in DNA sequences). Host genomic DNA released by 
necrotic acinar cells is elevated in serum as very early AP event and is recognized as a DAMP by 
TLR9 promoting an immune activation of sterile inflammation [9]. In addition, TLR9 induced by 
HMGB1 promotes the formation of CpG-DNA-TLR9 complex. HMGB1 interacts and 
preassociates with TLR9 in the endoplasmic reticulum-Golgi intermediate compartment (ERGIC), 
and hastens TLR9 redistribution to early endosomes in response to CpG-DNA. Loss of HMGB1 
leads to a defect in response to CpG-DNA in terms of IL-6, IL-12, TNF-α, and inducible nitric-
oxide synthase expression [13] . Interestingly, the genetic deletion of TLR9 in pancreatitis leads to 
reduced pancreatic edema, inflammation, and pro–IL-1β expression [14]. 
 
Systemic inflammatory response syndrome (SIRS) in AP: Role of TLRs  
SIRS is a clinical condition characterized by a specific physiological alteration of body 
temperature, white blood cell count, heart and respiratory rates. SIRS and sepsis may be 
differentiated by the presence or absence of a focus of infection. AP represents one of the most 
common non-infectious causes of SIRS [15]. 
 In AP, SIRS leads to distant organ damage, hypotension or hypoperfusion and MODS, which is 
the primary cause of morbidity and mortality in this condition. 
TLRs have been shown to play a major role in the development of SIRS. However, the recognition 
of PAMP by TLRs is not able to explain the etiology of SIRS or the pathogenesis of such “sterile 
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conditions” as ischemia and atherosclerosis, where no infection can be found. Zhai et al. reported 
that ischemic injury to the liver does not occur in mutant mice hosting a non-functional TLR4, and 
that the activation of TLR4 is not mediated by lipopolysaccharide (LPS), the archetypic agonist 
for TLR4 [16]. In addition, the ability of heparin sulfate and pancreatic elastase to induce SIRS is 
greatly diminished in TLR4-mutant mice [17]. 
A central role in the initiation, maintaining and progression of AP to SIRS is played by pro-
inflammatory mediators such as tumor necrosis factor (TNF) and IL-1, IL-6, IL-8, IL-10, PAF, 
C5a and ICAM-1 [18]. Their secretion and expression is closely regulated by the activation of 
gene promoters through NF-κB, which is the ending point of TLRs signaling pathway [19]. 
Moreover, TLR2 and TLR4 seem to be involved in lung and liver injuries as complications of AP 
[20]. 
 
Therapeutic perspectives 
Despite a lack of studies specifically evaluating the role of TLR-modulation in the clinical setting 
of AP, there is a growing body of evidence that both the TLRs and downstream TLR signalling 
pathways may be promising therapeutic targets (Table 2).  
Several agents have been proposed to modulate TLR4 activities. Eritoran, is a structural inhibitor 
of the lipid A portion of LPS, has been shown to inhibit TLR4 [21]. On the other hand, Resatorvid 
(TAK 242) is a selective inhibitor of signalling from the intracellular domain of TLR4 [22]. 
However, a non-significant reduction in mortality rate in patients with severe sepsis has been 
reported [23,24]. Therefore, the potential use of TLR4 antagonists in patients with AP or SIRS is 
still controversial. 
TLR9 is important DAMP receptor upstream of inflammasome activation, and its antagonism 
could provide a new therapeutic strategy for treating AP. In 2011, Hoque et al. revealed that 
components of the inflammasome (apoptosis-associated speck-like protein containing a caspase 
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recruitment domain [ASC], NLRP3, caspase-1), as well as TLR9, were essential for CIP 
development in wild-type mice and mice deficient in inflammasome components. Pretreatment 
with IRS954 (TLR9 antagonist) reduced pancreatic edema, inflammatory infiltrate, pancreatic 
necrosis and lung inflammation in taurolithocholic acid 3-sulfate-induced AP [25]. 
The inhibition of HMBG1, by using of blocking antibodies, decreases pancreatic injury and lung 
inflammation in an experimental model of severe AP [26]. Similarly, pharmacologic antagonism 
of both TLR9 and TLR7 decreases acinar cell necrosis and lung injury in an experimental model 
of severe AP [25]. 
 Lysosomal acidification is required for endosomal TLR-mediated immune responses. 
Chloroquine, through the inhibition of endosomal acidification, has been shown to reduce 
pancreatic injury and mortality in an experimental AP model [27].  
Furthermore, the recombinant IL-1 receptor antagonist has been shown to decrease pancreatic 
injury and inflammation [28].  
Peroxisome proliferator-activated receptor-α (PPAR-α) has attracted considerable attention for its 
anti-inflammatory properties. It has been reported that the administration of the PPAR-α agonist 
WY14643 in rats with CIP reduced amylase, lipase, myeloperoxidase activity, as well as IL-6, and 
ICAM-1 levels. Moreover, the TLR2 and TLR4 mRNA and proteins were markedly decreased by 
WY14643, along with IL-6, ICAM-1, and TNF-α mRNA levels, suggesting for a potential use of 
WY14643 in AP attenuation [29]. 
 
Role of TLRs in Diabetes Mellitus and its complications 
Diabetes is among the leading causes of death and disability affecting more than 348 million 
people worldwide [30]. Its incidence is rapidly increasing, and by 2030, this number is estimated 
to almost double [31]. A growing body of evidence has indicated that diabetes and its 
complications underlie a proinflammatory state characterized by elevated plasma C-reactive 
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protein, cytokines (IL-1, TNF-α, IL-6), chemokines, adhesion molecules, and monocyte activity. 
Furthermore, the activation of the innate immune system via TLRs, TLR2 and TLR4 in particular, 
seems to play a key role in the pathogenesis of both type 1 (T1DM) and type 2 diabetes mellitus 
(T2DM).  
While apoptosis of pancreatic β-cells, after a long sequence of autoimmune processes, appears to 
be the last step in the development of T1DM, the initial event in the pathogenesis of T1DM has 
not been cleared, although several authors proposed the sensing of DAMP from β-cells by TLR2 
on dendritic cells (DCs) as the first event. An increase in receptors and mRNA expression of 
TLR2 and TLR4 in monocytes was reported from patients with T1DM, without vascular 
complications, compared to healthy controls [32], as well as an upregulation of downstream 
targets of TLR signaling including MyD88, TRIF, phosphorylated IL-1 receptor-associated 
kinase, and NF-κB. In addition, elevated TRL2 and TLR4 expressions are significantly associated 
with glycemic control and advanced glycation end products. Knockdown of both TLR2 and TLR4 
resulted in a 76% decrease in high glucose-induced NF-κB response, suggesting an addictive 
effect [32−34]. Kim et al. found that diabetogenic T cell priming and the development of 
autoimmune diabetes were significantly inhibited in TLR2-null NOD mice. These data suggest 
that TLR2 blockade could be used in the treatment of autoimmune diabetes [35]. Furthermore, 
Mohammad and colleagues showed that TLR2 and TLR4 expression was increased in T1DM non-
obese mice and correlated with NF-κB activation in response to LPS. These results were also 
confirmed in a study in streptozotocin-induced diabetic mouse models [36]. 
TLRs seem to be involved even in the pathogenesis of T2DM. An increased mRNA expression of 
TLR2 and TLR4 in peripheral monocytes and increased TLR2 expression only in subcutaneous 
adipose tissue in T2DM was observed [37]. Moreover, an excess of glucose and free fatty acid 
(FFA) induced elevated TLR2 and TLR4 mRNA and protein expression in monocytes from 
patients with untreated T2DM [38]. Similarly, TLR2 and TLR4 mediate FFA-induced activation 
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of inflammatory pathways and metabolic signaling in insulin resistance, mainly though NF-κB 
activation [39,40].  
Adipose tissue appears to be a major site of production of inflammatory mediators, as a result of 
the cross-talk between adipose cells, macrophages, and other infiltrating immune cells. An 
increased TLR2 expression has been demonstrated in subcutaneous adipose tissue of patients with 
T2DM [41]. Similarly, an increased TLR4 gene and protein expression was found in the muscle 
biopsies from obese subjects and patients with T2DM compared to thin subjects, along with an 
increase in NF-κB signaling and release of IL-6 and TNF-α [42]. 
The activation of TLR4 induces inflammation in adipocytes in human and murine models of 
T2DM [43,44]. A recent study showed an increase in TLR-expressing B cells in patients with 
T2DM, whereas no changes in TLR expression on monocytes were observed in diabetic patients 
on treatment with anti-inflammatory medications [45]. Notably, polymorphisms in the TLR3 gene 
seem to be associated to the risk of T1DM. In fact, rs5743313 and rs117221827 polymorphisms 
were associated with an early age at diagnosis and a worse glycemic control [46]. While the 
presence of TLR4 +3725G/C polymorphism seems to be a novel protective factor against T2DM 
[47], the presence of a nonsense polymorphism (R392X) in TLR5 gene seems to protect from 
obesity and to predispose to T2DM [48]. However, these results should be investigated in 
prospective series. Of note, exercise, but not diet-induced weight loss, can modulate the role of 
TLRs in diabetes [49,50]. 
Most interestingly, several studies reported correlation between TLR expression and developing of 
diabetic complications. Experimental studies demonstrated that TLR2 and TLR4 could be 
important participants in the progression of atherosclerosis in diabetes [51,52]. 
Furthermore, TLR4 is upregulated in diabetic cardiomyocytes and plays a role in regulating lipid 
accumulation in cardiac muscle after the onset of type 1 diabetes, which may contribute to cardiac 
dysfunction [53].  
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Therapeutic perspectives 
An improved understanding of the mechanisms linking inflammation to diabetes mellitus has 
stimulated interest in targeting inflammatory pathways as a part of the strategy to prevent or to 
control diabetes mellitus and its complications. However, the current strategies to decrease 
inflammation in diabetes are empirical and some of these include statins, which can reduce TLR2 
and TLR4 expression [54], PPAR-γ agonists, angiotensin receptor blockers (ARBs) and omega-3 
fatty acids. In addition, phytochemicals may be also employed, such as D vitamin [55], orange 
juice [56] and citrus flavonoid naringenin [57]. 
To date, there are no approved therapeutic agents targeting TLRs for diabetes. Recently, the 
effects of immune tolerance, induced by chronic administration of TLR2 agonist Pam3CSK4, and 
Dipeptidyl peptidase 4 (DPP4) inhibitors have been investigated. Diabetogenic T cell priming by 
DCs was attenuated by chronic treatment with Pam3CSK4, indicating DC tolerance. The 
association with DPP4 could achieve normoglycemia by TLR2 tolerization in combination with 
DPP4 inhibition but not by TLR2 tolerization or DPP4 inhibition alone [58]. In the same view, the 
use of TLR9 antagonist oligodeoxynucleotide or chloroquine inhibited bone marrow-derived DCs 
activation and CD8(+) T cell priming in response to CpG, thus delaying the spontaneous onset of 
diabetes in NOD mice [59]. 
At present, a phase II trial (NCT01151605) is ongoing to evaluate the suppression of TLRs by 
insulin in lean, obese and T2DM patients. Another study (NCT01740817) is  running to determine 
whether a lipid infusion can up-regulate TLR4 signaling in human subjects with obesity and/or 
diabetes and an observational trial (NCT01561664) is evaluating the regulation of inflammation in 
obese patients by muscle and fat biopsy. Finally, a phase 4 study (NCT01250340) is assessing the 
role of TLRs in the pathophysiology of T2DM and associated atherosclerosis in patients treated 
with aspirin or placebo.  
In the last years, a major focus has been reserved to the relationship among exercise, inflammation 
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and innate immunity. The expression of TLR2 and TLR4 on human monocytes in vivo is 
markedly reduced by strenuous exercise [60]. Moreover, it has been reported that down-regulation 
of TLR2 and TLR4 expression was associated with improved insulin sensitivity after diet-induced 
weight loss in human subjects with abnormal glucose tolerance and metabolic syndrome. 
 
Role of TLRs in pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC), an aggressive cancer, interacts with stromal cells to 
produce a highly inflammatory tumor microenvironment in order to promotes tumor growth and 
invasiveness. TLRs mediate interactions between environmental stimuli and innate immunity and 
trigger proinflammatory signaling cascades. It is likely that TLR activation, either directly or 
indirectly via stromal cell activation, promotes an aggressive phenotype in the at-risk epithelial 
cells, which, in turn, induces oncogene-induced senescence (OIS). The ligation of TLRs causes 
derangements in several tumor suppressor proteins (such as p16, p21, p27, p53 and pRb), STAT3 
activation and interfaces with Notch, NF-κB and MAP kinase pathways [61]. These effects seem 
to be due to stromal cells, since chimeric mice with Tlr4−/− or Tlr7−/− bone marrows, were partially 
protected from pancreatic carcinogenesis [61,62].  
Zambirinis and colleagues explored the effects of TLR-MyD88/TRIF signaling on pancreatic 
carcinogenesis in p48Cre;LslKrasG12D pancreatic cancer mouse model. Mice treated with either 
TLR3, TLR4 or TLR7 agonists exhibited a dramatic acceleration of pancreatic cancer progression, 
characterized by more advanced pre-invasive (PanIN) lesions and a higher number of invasive 
foci, as well as increased fibrosis and augmented immune infiltrate [63].  
The inhibition of MYD88 in DCs leads CD4+ T cells toward a TH2 profile and to an acceleration 
of cancer progression by perpetuating inflammation [62]. Similarly, the activation of STAT3 and 
the upregulation of NOTCH receptors and ligands occur in both the epithelial and the stromal 
component of PDAC and contribute via NFκB and MAPK to the aggressive tumor phenotype 
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induced by TLR7 activation [64]. 
Supporting data came from Ochi et al. They revealed the primary role for DCs in pancreatic 
carcinogenesis and showed that the blockade of TLR4 signaling, via TRIF, is protective against 
pancreatic cancer. In the same study, they showed that MyD88 inhibition, by augmenting the DC–
TH2 axis, can exacerbate pancreatic inflammation and neoplastic transformation [62].  
LPS-related TLR4 signaling could be a triggering factor in the initiation and progression of 
pancreatic cancer [65,66], directly modulating the transition from pancreatic inflammation to 
pancreatic cancer in genetically engineered mouse models [62,67]. In PDAC tissue, TLR4 is 
expressed and its levels have been shown to correlate with tumor size, lymph node involvement, 
venous invasion, and pathological stage [68]. Moreover, TLR4 expression in pancreatic cancer 
cells is up-regulated via HIF-1α in response to hypoxic stress and underscore the crucial role of 
HIF-1α-induced TLR4 in PDAC tumor growth [69]. Patients with overexpressed TLR4 or 
overexpressed HIF-1α had a significantly shorter survival period compared to the patients with 
normal expression, while longer survival (p=0.014) was reported among patients with neither 
TLR4 nor HIF-1α overexpression [70]. 
The epithelial–mesenchymal transition (EMT) in pancreatic cancer promoted by M2-polarized 
tumor-associated macrophages partially involves the TLR4/IL-10 signaling pathway (Figure 3). 
Indeed, the application of TLR4 siRNA and neutralizing antibodies against TLR4 and IL-10 
markedly inhibited the reduction of epithelial marker E-cadherin and the upregulation of 
mesenchymal markers snail and vimentin induced by TLR4 [71].  
 
Therapeutic perspectives 
TLR2 seems to be expressed in over 70% of pancreatic tumors but not in normal pancreas tissue. 
The potential use of synthetic TLR2 agonists for the enhancement of cancer immunotherapy is an 
active area of research. Three mechanisms are involved in the antitumor activity of TLR2: 
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induction of apoptosis in TLR2-positive tumors, enhancement of the innate and T-cell immunity, 
and improvement of cytotoxic antibody function. Huynh and colleagues demonstrated the PDAC 
specific retention of the fluorescently labeled compound IRDye800CW-Mpr-, in vivo, using mice 
bearing TLR2 expressing xenografts [72]. The intraoperative use for increasing the detection of 
negative resection margins should be prospectively investigated. 
A phase I/II trial examined the TLR 2/6 agonist MALP-2 in combination with gemcitabine in 
patients with locally advanced PDACs. Ten patients were injected intratumourally during surgery 
with 20-30 micrograms of MALP-2 followed by postoperative chemotherapy. The median 
survival was 9.3 months, with two patients still alive after 31 months [73]. 
Immune responses are impaired in pancreatic cancer patients. A promising strategy for interfering 
with tumor immune evasion can be represented by the combination of vaccines based on immune 
stimulatory complexes (ISCOM) and TLR agonists. Jacobs et al. investigated the efficacy of an 
ISCOM vaccine alone or in combination with the TLR9 agonist CpG in a murine pancreatic 
carcinoma model. Unfortunately, ISCOM vaccine, alone, did not affect tumor growth, but its 
combination with CpG enhanced cytotoxic T lymphocyte responses and induced regression of 
pancreatic tumors in a CD8+ T cell-dependent manner [74].  
Other data on the potential role of TLR9 in cancer were showed by Rosa et al. A TLR9 agonist 
immunomodulatory oligonucleotide (IMO) alone or in combination with cetuximab was 
investigated in subcutaneous colon and orthotopic pancreatic cancer models harboring K-Ras 
mutations and resistance to EGFR inhibitors. They reported that IMO markedly inhibited growth 
of K-Ras mutant colon and pancreatic cancers in vitro and in nude mice and cooperated with 
cetuximab via multiple mechanisms of action, suggesting for its use in cetuximab-resistant 
colorectal and pancreatic cancers [75]. 
Zhou et al. evaluated whether 6-shogaol, a hydroxycinnamic acid derivative extracted from 
ginger, could suppress pancreatic cancer progression and potentiate response to gemcitabine 
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treatment in vitro and in vivo. They showed that 6-shogaol prevented the activation of TLR4/NF-
κB signaling and suppressed key cell survival regulators including cyclooxygenase 2 (COX-2), 
cyclinD1, survivin, cIAP-1, XIAP, Bcl-2, and MMP-9. In addition, 6-shogaol inhibited the growth 
of human pancreatic tumors and sensitized them to gemcitabine by suppressing of TLR4/NF-κB-
mediated inflammatory pathways linked to tumorigenesis [76]. 
MicroRNAs (miRNAs) are a class of highly conserved non-coding small RNAs. It’s been shown 
that several miRNAs, including miR-301a, can affect the expression of different proteins in the 
NF-κB pathway in immune cells, thus affecting the production of inflammatory mediators such as 
IL-1β and TNFα. miR-301a is specifically over-expressed in a number of cancers, including 
PDAC [77]. 
miR-301a down-regulates its target gene, NF-κB repressing factor (NKRF), by enhancing NF-κB 
activity. The downregulation of miR-301a expression leads to a suppressed TLR-dependent innate 
immune response by reducing macrophage COX-2 and IL-6 expression. These data suggest that 
miR-301a inhibition or NKRF up-regulation can reduce NF-κB target gene expression and tumour 
growth, representing a potential therapeutic approach in patients with PDAC [78].  
 
Conclusions 
Pancreatic inflammation, diabetes and tumor progression involves TLR-mediated irregular and 
uninhibited production of proinflammatory cytokines, chemokines, and also immunosuppressive 
cytokines, suggesting that the discovery of TLR antagonists might be an ideal therapeutic strategy. 
However, TLR antagonists could pose the risk to compromise host immunity, mostly in cancer 
patients. Although the use of TLR agonists and antagonists may provide a benefit in patients with 
pancreatic cancer and disease, interest is centered on the potential to complement existing modes 
of therapy with radiation, monoclonal antibodies or cytotoxic drugs.  
In summary, TLRs represent promising therapeutic targets in patients with AP, diabetes and 
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PDAC, although further research and elucidation of involved mechanisms are warranted in order 
to explore their potential future clinical implications. 
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Table legends 
Table 1. Ligand recognition by Toll-like receptors. 
Table 2. Selection of agents under evaluation in the treatment of AP. IL = Interleukin; MIF: 
Migration inhibitory protein;. TLR: Toll-like receptor; TNF-α = Tumor necrosis factor-α. 
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Figure legends 
Figure 1. TLR signalling pathways. All TLRs except TLR3 can activate a Myeloid differentiation 
primary response protein 88 (MyD88)-dependent pathway. TLR2 and TLR4 also recruit a 
MyD88-like adaptor molecule Mal, thus activating NF-κB through an IkB kinase (IKK) complex. 
NF-κB then translocate to the nucleus where it binds to κB promoter elements resulting in the 
expression of inflammatory cytokines, such as TNF-α, IL-1 and IL-6. TLR3 via the TIR-domain 
containing-adaptor inducing interferon-b (TRIF) leads to the activation of interferon regulatory 
factor (IRF) 3. IRF3 dimerises and translocates into the nucleus and binds to interferon-sensitive 
response element (ISRE) motifs, thus promoting the expression of interferon (IFN)-α/β. TLR4 can 
also utilize the TRIF-related adaptor molecule (TRAM) for the activation of NF-κB and IRF3. On 
the other hand, TLR7 and TLR9 can also activate IRF3 related molecules such as IRF7, leading to 
the expression of IFN-α/β. 
Figure 2. The sterile inflammatory response in acute pancreatitis. Sterile stimuli that include 
damage-associated molecular patterns (DAMPs), sterile particulates and intracellular cytokines 
released from necrotic cells can activate the host immune system to induce sterile inflammation. 
HMGB1 = high-mobility group box 1; IL-1 = interleukin-1; IL-1R = IL-1 receptor; NLRP3 = 
NOD-, LRR- and pyrin domain-containing 3; RAGE = receptor for advanced glycation end-
products; TLR = toll like receptor. 
Figure 3. Epithelial-mesenchymal transition (EMT) is proposed to play a role in pancreatic cancer 
invasion. In response to inflammation, mediated by TLR4/IL-10 axis, epithelial cells lose their cell 
polarity and gain migratory and invasive properties to become mesenchymal cells. Loss of E-
cadherin is considered to be a fundamental event in EMT. Carcinoma cells in primary tumor lose 
their E-cadherin-mediated cell-cell adhesion and break through the basement membrane with 
increased invasive properties, and enter the bloodstream through intravasation. 
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Fig. 2 
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Fig. 3 
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Table 1 
TLRs Localization PAMP Origin of PAMP 
TLR1 Plasma membrane Triacyl lipopeptides 
N. meningitidis 
Triacyl lipopeptides Bacteria, 
mycobacteria 
TLR2 Plasma membrane 
Glycoinositolphospholipids, 
Glycolipids, Haemagglutinin, 
Lipoarabinomannan, 
Lipoprotein/lipopeptides, 
Lipoteichoic acid, Zymosan,  
Peptidoglycan,  Phenol-
soluble modulin, Porins 
Trypanosoma cruzi, Treponema 
maltophilum, Virus, 
Mycobacteria, Various pathogens, 
Gram-positive bacteria, Gram-
positive bacteria, S. epidermidis, 
Neisseria, Fungi 
TLR3 Endosome Double-stranded RNA Virus 
TLR4 Plasma membrane 
Envelope protein, Fusion 
protein, Heat-shock protein 
60, Lipopolysaccharide, 
Taxol 
Mouse-mammary tumour virus, 
Respiratory syncytial 
Virus, Chlamydia pneumoniae, 
Gram-negative bacteria, Plants, 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipopeptides, Zymosan, Lipoteichoic acid  
Mycoplasma, Gram-positive 
bacteria, Fungi 
TLR7 Endosome Single-stranded RNA Virus 
TLR8 Endosome Single-stranded RNA Virus 
TLR9 Endosome DNA (CpG), Haemozoin Bacteria, virus, Plasmodium spp., Rhodnius spp, Schistosoma spp. 
TLR10 Endosome Not determined Not determined 
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Table 2 
 
Agent Description Activity in AP 
WY14643 Peroxisome proliferator-
activated receptor-α agonist 
Markedly decreases TLR2 and TLR4 mRNA and 
proteins, along with IL-6, ICAM-1 and TNF-α 
mRNA levels 
Chloroquine 
Weak base that accumulates 
in the lysosomes and 
increases their pH 
Inhibit endosomal acidification, required for some 
TLR activation 
L-Arg 
2-Amino-5-
guanidinopentanoic Acid 
(amino acid) 
Down-regulates TLR2 and TLR4 and stimulates 
the production of nitric oxide, meliorating lung 
and liver damages 
IRS954 TLR9 antagonist Reduces pancreatic edema, inflammatory infiltrate, 
and apoptosis 
Emodin 1, 3, 8-trihydroxy-6-
methylanthraquinone Suppress TLR4 up-regulation 
Eritoran Structural inhibitor of the lipid A portion of LPS Inhibits TLR4 activity 
TAK 242 Cyclohexene derivative Inhibits TLR4 signaling 
Danshen 
Dried root and rhizome of the 
medicinal plant Salvia 
miltiorrhiza Bunge (Labiatae) 
Inhibits the binding of LPS to TLR4, reducing 
bacterial translocation and liver injury. 
Anti-MIF 
antibody 20 µg/animal 
Suppress the AP-induced elevation of TLR-4 
pulmonary expression 
Baicalin Flavonoid, prolyl 
endopeptidase inhibitor Suppress TLR4 up-regulation 
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Highlights 
 Toll-like receptors mediate interactions between environmental stimuli and innate immunity. 
 TLRs play a crucial role in the development of acute pancreatitis and SIRS.  
 TLR2, TLR4, TLR7 and TLR9 are involved in type 1 and 2 diabetes mellitus. 
 TLRs promote pancreatic carcinogenesis and epithelial–mesenchymal transition. 
 TLRs represent a promising target for pancreatitis, diabetes and pancreatic cancer. 
 
